/
Other
Relapsed/refractory
65
Pipeline Programs↗
54
Active Trials↗
49
Companies Involved↗
Relapsed/Refractory is a moderately active landscape with 65 programs across 49 companies. The most active players are TJ Biopharma Co., Ltd., Hebei Senlang Biotechnology Inc., Ltd., Chongqing Precision Biotech Co., Ltd. 2 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical5
Phase 113
Phase 245
Approved
No programs
Analysis
Modality Breakdown
71%
Small molecule
42 of 59 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 59 classified programs, each share of the total. Modality classified for 100% of 65 pipeline programs.
Analysis
Trial Status
150
clinical trials
Completed41 · 27%
Recruiting36 · 24%
Unknown status27 · 18%
Terminated15 · 10%
Active, not recruiting11 · 7%
Withdrawn11 · 7%
Other9 · 6%
Clinical Trials
Trial Activity
150 trials
Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.
Recruiting·SShanghai Tongji Hospital, Tongji University School of Medicine·Phase 1·NCT06375161·12 enrolled
Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA
Recruiting·—·Phase 2·NCT05922839·22 enrolled
Page 1 of 10
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)